Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07068178 | Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study(ICI-HIPET) | not yet recruiting | Phase 2 | 30 | Jing LiOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06839144 | Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression(OC-POP-PT) | recruiting | Phase 2 | 60 | Tel-Aviv Sourasky Medical CenterOTHER_GOV |
| 1 |
| Jul 11, 2025 |
| clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07047001 | Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma | active not recruiting | Phase 2 | 60 | Dong WenOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06942377 | Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy | not yet recruiting | Phase 2 | 140 | Peking University People's HospitalOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07053462 | CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk | recruiting | Phase 1 / Phase 2 | 90 | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLCOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07022535 | Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(PRESELECT-0) | recruiting | Phase 2 | 18 | The University of Hong KongOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07023484 | Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(Preselect-1) | recruiting | Phase 2 | 126 | The University of Hong KongOTHER | 2 | Jul 2, 2025 | clinicaltrials |
| NCT07044349 | Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | not yet recruiting | Phase 2 | 72 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Jun 30, 2025 | clinicaltrials |
| NCT06602063 | Surgery for Relapsed Ovarian Cancer in Precision | not yet recruiting | Phase 1 / Phase 2 | 33 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 27, 2025 | clinicaltrials |
| NCT02817958 | Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis(MEGACEP) | active not recruiting | Phase 2 | 37 | UNICANCEROTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07034053 | Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 50 | Ekaterina LaukhtinaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07038304 | The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)(OLYMPIAN) | recruiting | Phase 2 | 35 | University Medical Center GroningenOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04249154 | Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer(PROMPT) | recruiting | Phase 2 | 77 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05191680 | TherApeutics in Early ProState Cancer (TAPS02) | recruiting | Phase 2 | 90 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jun 20, 2025 | clinicaltrials |
| NCT07003620 | Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial | recruiting | Phase 2 | 34 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06073184 | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium(WE-FiERCE) | not yet recruiting | Phase 2 | 71 | University Health Network, TorontoOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06998394 | A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer | recruiting | Phase 2 | 30 | Xiangbo WanOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06049355 | EMBRACE: Exercising Together | recruiting | Phase 2 | 400 | OHSU Knight Cancer InstituteOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT03101995 | Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease | recruiting | Phase 2 | 18 | National Institute of CancerologíaOTHER_GOV | 1 | May 28, 2025 | clinicaltrials |
| NCT06990516 | SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 90 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02571725 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 50 | New Mexico Cancer Research AllianceOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04575961 | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer(PERCEPTION) | active not recruiting | Phase 2 | 33 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06986057 | Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer | not yet recruiting | Phase 2 | 28 | Shandong Tumor HospitalOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT06383052 | A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC | active not recruiting | Phase 1 / Phase 2 | 30 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06981858 | A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 34 | Chongqing University Cancer HospitalOTHER | 0 | May 21, 2025 | clinicaltrials |
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT06972628 | Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 | recruiting | Phase 2 | 30 | Ebrahim S DelpassandOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06973421 | Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 35 | Fudan UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06971211 | Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC(PARTOM) | recruiting | Phase 2 | 40 | Jianbin BiOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05795244 | Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) | recruiting | Phase 2 | 30 | Yonsei UniversityOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06139575 | Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 90 | Bivision Pharmaceuticals, Inc.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT04253262 | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06957561 | Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer(DIVON) | not yet recruiting | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT03689699 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | active not recruiting | Phase 1 / Phase 2 | 59 | Mark SteinOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06942416 | Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer | recruiting | Phase 2 | 36 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06415318 | TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer | recruiting | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06702995 | Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 307 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06686030 | Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | recruiting | Phase 2 | 150 | AkesoINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06480110 | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 30 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06705075 | Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE | recruiting | Phase 2 | 80 | Thomas Jefferson UniversityOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06916117 | Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC | not yet recruiting | Phase 2 | 30 | RenJi HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06917092 | QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer(QLPPEC/GOG-003) | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer(LuCAB) | active not recruiting | Phase 1 / Phase 2 | 35 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Apr 6, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2025source: clinicaltrials